The Keck Biophysics Facility is a center for molecular biophysical research which provides Northwestern groups with advanced equipment outstanding services, specialized training, and technical expertise. Created in 1998 by Northwestern University's Center for Structural Biology with a grant from the W.M. Keck Foundation and additional support from the NIH, the Rice Foundation, and the Robert H. Lurie Comprehensive Cancer Center (RHLCCC), Keck has been one of Northwestern's Shared Resources since April 1,1999. The Keck Facility has a set of 20 advanced instruments that together allow for integrated biophysical analyses of macromolecular structure, interactions, and function. Each particular biophysical instrument, such as a circular dichroism spectrometer, a fluorimeter, or a calorimeter, provides just one or a few individual facets of a complex overall picture. Data from many individual biophysical studies - using a diverse set of particular instruments - must be combined to yield the needed comprehensive picture. In the past 5 years, the facility has been thoroughly modernized with state of the art equipment that replaced older instruments, addition of new technologies and capabilities, a modern internet-based reservation/administration system and many upgrades. In parallel, the Facility has invested in personnel training in order to provide users with outstanding technical expertise and assistance. To better accommodate the needs of our diverse user base, we are offering a flexible array of services. Besides counseling, training and assistance, full service options are also available on all the Facility's instruments. The Keck Facility currently has 506 active users from 90 research groups (students, postdoctoral fellows, and faculty who are authorized to use Keck Facility equipment). Researchers affiliated with the RHLCCC account for over 80% ofthe total utilization ofthe Facility. As such, the Keck Biophysics Facility is a critical resource for cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA060553-19
Application #
8588633
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2018-07-31
Budget Start
2013-09-16
Budget End
2014-07-31
Support Year
19
Fiscal Year
2013
Total Cost
$150,127
Indirect Cost
$53,005
Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Brahmer, J R; Lee, J W; Traynor, A M et al. (2014) Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer 50:302-8

Showing the most recent 10 out of 316 publications